Cocrystal Pharma, Inc. · NASDAQ:COCP
Cocrystal Pharma — Investor Presentation (January 2024)
22 slides from Cocrystal Pharma's investor presentation, Jan 8, 2024
Slide 1: Potent antivirals to combat some of the most serious diseases facing humanity
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the market opportunities for the treatment of acute and chronic viral diseases which are the focus of our progra
Slide 3: About Cocrystal Pharma
About Cocrystal Pharma Advancing programs in high-value antiviral drug targets * Pandemic and seasonal influenza * Pandemic norovirus » Pandemic coronavirus and respiratory viruses Applying powerful, proprietary Drug candidates with clinically validated mechanisms of action drug discovery platform +
Slide 4: Investment Highlights
Investment Highlights. » Targeting multibillion-dollar, global markets for the treatment of acute and pandemic viral diseases « Proprietary structure-based drug-discovery platform technology provides opportunity for discovery and development of novel, potent, broad-spectrum drug candidates e Advanci
Slide 5: Program
Program Influenza A Influenza A/B Norovirus & Coronavirus Coronavirus (Licensed) Norovirus Respiratory viruses Candidate Oral PB2 inhibitor cDr-988 Inhaled PB2 inhibitor cpI-988 Replication inhibitors ee eee hese 1 study planned in 2024 Lead optimization ongoing Protease inhibitor CDI-45205 Replicat
Slide 6: Discovery Platform Technology Direct-Acting Antivirals
Discovery Platform Technology Direct-Acting Antivirals Cocrystal’s technology platform provides potential for novel drug candidates at reduced development timelines and costs Grow drug target Select Drug Hit-to-lead Lead . . — x-ray crystals binding pocket process optimization Direct-Acti ng Antivir
Slide 7: Pandemic and Seasonal Influenza Program
Pandemic and Seasonal Influenza Program
Slide 8: Pandemic and Seasonal Influenza: A Major Global Health Concern
Pandemic and Seasonal Influenza: A Major Global Health Concern * 1 billion cases, 3-5 million severe illnesses and up to 650,000 deaths worldwide annually’ * Not well managed with currently approved vaccines having only 40-60% effectiveness? ° On average ~8% of the U.S. population contracts influenz
Slide 9: Influenza Development Programs Focused on Therapeutic and Prophylactic
Influenza Development Programs Focused on Therapeutic and Prophylactic Replication Inhibitors Clinical assets for pandemicand seasonal influenza Promising Early-Stage Programs Oral PB2 inhibitor Inhaled PB2 inhibitor Replicati hibit. Gace conan eplication inhibitors = Ongoing Phase 2a = Ongoing GLP
Slide 10: CC-42344 Binds to Highly Conserved Active Site of Influenza A PB2 Protein
CC-42344 Binds to Highly Conserved Active Site of Influenza A PB2 Protein Cocrystal proprietary drug discovery platform technology Highly pathogenic influenza A strains HSN1 ~ C@CRYSTAL —— tt
Slide 11: Development of Inhaled CC-42344
Development of i GC42344 Advantages of inhalation antiviral therapy * Directly targets infected respiratory epithelial cells * Achieves higher accumulation of drug in the pulmonary system * Produces rapid clinical response » * Reduces potential systemic side effects " C@CRYSTAL
Slide 12: Influenza-Infected Lung Epithelium
nfluenza-Infected Lung Epithi ium Uninfected human bronchial airway epithelia Influenza A gm H1N1 infection ay Gells are killed by HIN1 virus,and most cilia are destroyed - ~ NOo-CC-42344 Favorable safety profile: No toxicity in CC-42344- treated human lung epithelium Showed potent antiviral activit
Slide 13: CC-42344: Potential Influenza Therapeutic and Prophylactic Treatment
CC-42344: Potential Influenza Therapeutic and Prophylactic Treatmen ° Favorable safety profile ° Potent, broad-spectrum activity against pandemic and seasonal strains High barrier to resistance ° Superior pulmonary pharmacology: high exposure and long half-life, EC50 >5,000-fold by 4 days post-singl
Slide 14: Norovirus and Coronavirus Programs
Norovirus and Coronavirus Programs
Slide 15: Norovirus Infection: No Approved Treatments or Vaccines Available
Norovirus Infection: No Approved Treatments or Vaccines Available Norovirus 7 ee 2 Norovirus Gil.4 Leading causative pandemic agent of acute viral outbreaks gastroenteritis CDC: Norovirus Disease in the United States https /Avww cde gov/norovirus/ourden html
Slide 16: Norovirus: Large Market with No Approved Treatments or Vaccines
Norovirus: Large Market with No Approved Treatments or Vaccines * Highly contagious virus that causes symptoms of acute gastroenteritis including nausea, vomiting, stomach pain and diarrhea * Major cause of gastrointestinal illness in closed and crowded environments including hospitals, nursing home
Slide 17: Norovirus and Coronavirus Development Programs Focused on Broad-spectrum Antivirals
Norovirus and Coronavirus Development Programs Focused on Broad- spectrum Antivirals Clinical assets for pandemicand epidemic norovirus and coronavirus Promising Early-Stage Programs Oral pan-norovirusand pan-coronavirus Replication and protease Protease inhibitor, CDI-988 inhibitors = Potential dua
Slide 18: Seasoned Leadership
Seasoned Leadership Sam Lee, Ph.D. Co-Chief Executive Officer & President 25+ years of antiinfective drug discovery research experience, including HCV and influenza antivirals; played key role in early development of phosphoinositide 3- kinase (PI3K) detta inhibitor, Zydelig “ Zydelig James J. Marti
Slide 19: Experienced Board of Directors
Experienced Board of Directors Roger Kornberg, Ph.D. Co-founder, Chairman of the Board & Chairman of the Scientific Nobel Laureate in Chemistry ‘Welch Prize— highest award granted in the field of chemistry in the U.S. Leopald Mayer Prize— highest award granted in the field of biomedical sciences fro
Slide 20: Expanding Intellectual Property Portfolio
Expanding Intellectual Property Portfolio Coronavirus Norovirus * Issued patents in U.S. and major countries * Issued patents in U.S. and major countries * Pending U.S. provisional applications * Pending U.S. provisional applications Pandemic Influenza A HCV * PB2 (influenza A inhibitor) NSS5B (NNI)
Slide 21: Financial Snapshot
Financial Snapshot ~$20 Million 27,000 Average 3 month 1 Market cae. daily share volume* 10.3 Million Fully diluted shares Clean balance sheet No preferred shares No debt Cash sufficient to fund planned operations *Yahoo Finance (November 27, 2023) 2
Slide 22: Investment Highlights
Investment Highlights. » Targeting multibillion-dollar, global markets for the treatment of acute and pandemic viral diseases « Proprietary structure-based drug-discovery platform technology provides opportunity for discovery and development of novel, potent, broad-spectrum drug candidates e Advanci
Cocrystal Pharma — Investor Presentation (January 2024) on 6ix